By: Intervet  09-12-2011
Keywords: Dogs

Nobivac® Lyme has been shown to produce borreliacidal antibodies that are highly effective in killing Borrelia burgdorferi.1

In a tick challenge study:

  • 30 8-week old puppies were randomly assigned to two groups
  • 15 vaccinates and 15 controls received either Nobivac® Lyme or a placebo injection administered subcutaneously on Days 0 and 21
  • All dogs were challenged with live B. burgdorferi–infected ticks 3 weeks after the second dose
  • Ticks fed for 7 days, then were examined for B. burgdorferi
  • Evaluations in dogs included skin biopsies, joint tissue analyses, and assessment for clinical signs of disease


Nobivac® Lyme has also been shown to help prevent Lyme disease–associated joint abnormalities.1

Nobivac® Lyme helps prevent subclinical and clinical signs of illness due to Lyme disease.1

In dogs vaccinated with Nobivac® Lyme…

  • No B. burgdorferi were recovered from joint tissues
  • No inflammatory changes were seen in joint capsules 
  • No limb or joint disorders attributable to B. burgdorferi occurred 
  • No serologic evidence of exposure to B. burgdorferi was present

In control dogs…

  • 14 out of 15 had antibodies specific for B. burgdorferi
  • 10 out of 15 developed joint stiffness or lameness, or chronic joint inflammation (synovitis) 
  • 8 out of 15 had isolation of B. burgdorferi from the joint

1. LaFleur RL, Dant JC, Wasmoen TL, et al. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. Clin Vaccine Immunol. 2009;16(2):253–259.

Keywords: Dogs

Contact Intervet

Email - none provided

Print this page

Other products and services from Intervet



Client-owned dogs were vaccinated subcutaneously with a 1-mL dose of Nobivac® Lyme and boosted with an additional 1-mL dose 21 days later, for a total of 1,236 vaccine administrations. Mild, transient soft tissue swelling, which may occur at the injection site, is a typical response following subcutaneous vaccination with a whole-cell bacterin.



Nobivac® Lyme is a bacterin that contains two inactivated strains of Borrelia burgdorferi comprised of outer surface protein A and outer surface protein C. This bacterin is approved for the vaccination of healthy dogs as an aid in the prevention of subclinical arthritis caused by B. burgdorferi. Lyme is administered subcutaneously as an initial vaccination followed by a booster 2 to 4 weeks later.


NOBIVAC LYME - Lyme Disease Transmission

Soon after the tick takes its bloodmeal, OspA expression decreases and OspC expression increases, becoming the dominant outer surface protein. When a Borrelia-infected tick attaches to a dog, high levels of OspA are expressed by the Borrelia, which are residing in the tick’s midgut. Burgdorferi have different outer surface proteins that act as antigens and are expressed at various phases in the tick feeding cycle.


NOBIVAC LYME - Mechanism of Action

Nobivac® Lyme was specifically designed to target two key factors involved in the transmission of Lyme disease—OspA and OspC.1. OspC borreliacidal antibodies can kill Borrelia in the tick and in the dog. OspA borreliacidal antibodies can only kill Borrelia in the feeding tick. Nobivac® Lyme combines 2 isolates of Borrelia burgdorferi.